Written Comment Request:
Draft Jardiance Cost Review Study Report (Posted 3/16/2026)
In accordance with COMAR 14.01.04.05F(3), staff has posted the draft Jardiance Cost Review Study Report and is hereby requesting public written comment.
Comments may be submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Monday, March 30, 2026 to [email protected]
Please reference “Jardiance: Cost Review Study Report” in the subject line.
Written Comment Request:
Draft Farxiga Cost Review Study Report (Posted 3/16/2026)
In accordance with COMAR 14.01.04.05F(3), staff has posted the draft Farxiga Cost Review Study Report and is hereby requesting public written comment.
Comments may be submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Monday, March 30, 2026 to [email protected]
Please reference “Farxiga: Cost Review Study Report” in the subject line.
ARCHIVE:
Written Comment Request:
Jardiance UPL Amount and Methodology Document (Posted 2/17/2026)
In accordance with COMAR 14.01.05.06D(4), staff has posted its recommendation for a proposed UPL amount and methodology for Jardiance and is hereby requesting public written comment.
Comments were submitted in accordance with COMAR 14.01.01.05B(4) by close of business, Wednesday, March 4, 2026 to [email protected] .
Written Comment Packet
Comments Received from the following:
AARP
AimedAlliance
Boehringer Ingelheim USA Corporation
EACH/PIC Coalition
Healthcare Distribution Alliance
Maryland Healthcare for All Coalition
PhRMA
Unitarian Universalist Legislative Ministry of Maryland (UULM-MD)
Written Comment Request:
Farxiga UPL Amount and Methodology Documents (Posted 2/17/2026)
In accordance with COMAR 14.01.05.06D(4), staff has posted its recommendation for a proposed UPL amount and methodology for Farxiga and is hereby requesting public written comment.
Comments were accepted in accordance with COMAR 14.01.01.05B(4) by close of business, Wednesday, March 4, 2026 to [email protected]
Written Comment Packet
Comments Received from the following:
AARP
Aimed Alliance
AstraZeneca
EACH/PIC Coalition
Healthcare Distribution Alliance
Maryland Healthcare for All Coalition
PhRMA
Unitarian Universalist Legislative Ministry of Maryland (UULM-MD)
Written Comment Request - Revised Frameworks (Posted 2/2/2026)
In accordance with COMAR 14.01.05.06A and 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment on the revised framework documents for Ozempic and Trulicity.
Comments will be accepted through close of business February 17, 2026.
- Diabetes Patient Advocacy Coalition
- EACH/PIC
- Novo Nordisk
Written Comment Request: Posted 10/28/2024In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on:
Patient experience and clinician input regarding these drugs are of particular interest but all comments concerning these drug products are encouraged. Written comments were due by the close of business, Friday, November 8, 2024. Please submit written comments to
[email protected] with the subject line “(Drug Name) Comments.”
Drugs Referred to Stakeholder Council
The comment period for Drugs Referred to the Stakeholder Council begins April 10, 2024. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to [email protected] with “Drugs Referred to the Stakeholder Council Comment" in the subject line.
Drugs Referred to the Stakeholder Council
Comments Received for Drugs Referred to Stakeholder Council
Therapeutic Alternatives
The comment period for Therapeutic Alternatives (for Drugs Referred to the Stakeholder Council) begins April 10, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Friday, May 10, 2024. Comments may be submitted to [email protected] with “Therapeutic Alternatives" in the subject line.
The comment period for Therapeutic Alternatives for Drugs Referred to the Stakeholder Council begins April 11, 2024 for the therapeutic alternatives linked below. Comments are due by COB, Monday, May 13, 2024. Comments may be submitted to
[email protected] with “Therapeutic Alternatives" in the subject line.
Comments Received for Therapeutic Alternatives
Additional Information
